A5102774299- Inflammatory Bowel Disease
- Microscopic Colitis
- Dermatology and Skin Diseases
- Pharmacological Effects of Natural Compounds
- Tuberculosis Research and Epidemiology
- Asthma and respiratory diseases
- Transgenic Plants and Applications
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Adrenal Hormones and Disorders
- Monoclonal and Polyclonal Antibodies Research
- Antibiotic Resistance in Bacteria
- Diagnosis and treatment of tuberculosis
- Antibiotics Pharmacokinetics and Efficacy
- Gastrointestinal motility and disorders
- Atherosclerosis and Cardiovascular Diseases
- Pharmaceutical and Antibiotic Environmental Impacts
- Cardiovascular Disease and Adiposity
- Cancer Immunotherapy and Biomarkers
- Muscle Physiology and Disorders
- Toxin Mechanisms and Immunotoxins
- Lysosomal Storage Disorders Research
- Food Allergy and Anaphylaxis Research
Pfizer (United States)
2017-2024
University of Hong Kong
2020-2023
Pfizer (United Kingdom)
2021
Abrocitinib, an oral, once-daily, Janus kinase 1-selective inhibitor, is efficacious in moderate-to-severe atopic dermatitis with a manageable long-term safety profile. We aimed to provide updated integrated results for abrocitinib from available data accrued up maximum of almost 4 years patients the JADE clinical development program. Analysis included 3802 (exposure: 5213.9 patient-years) phase II monotherapy study (NCT02780167) and III studies MONO-1 (NCT03349060), MONO-2 (NCT03575871),...
Introduction: Tofacitinib is an oral, small molecule JAK inhibitor that being investigated for ulcerative colitis (UC). We present details of herpes zoster (HZ) infection events in the tofacitinib Phase (P) 2/3 UC program. Methods: Pooled analyses were performed 3 cohorts (C): C1, 8-week placebo-controlled doubleblind induction studies (1 P2 and 2 P3 [OCTAVE Induction 1 & 2]);1,2 C2, a 52-week maintenance study (OCTAVE Sustain); C3, all patients (pts) treated with 5 or 10 mg twice daily...
Introduction: Tofacitinib is an oral, small molecule JAK inhibitor that being investigated for ulcerative colitis (UC). The efficacy and safety of tofacitinib was evaluated in moderate to severe UC patients (pts) Phase (P) 3, randomized, placebo (PBO)-controlled induction maintenance studies.1 Methods: Safety data pts were pooled from 1 P2 2 P3 (8 wks) studies, (52 study ongoing long-term extension (LTE) study. Three cohorts (C) analyzed: C1, P2P3 studies; C2, study; C3, tofacitinib-treated...
Introduction: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). We present integrated analysis non-melanoma skin cancer (NMSC) in tofacitinib Phase (P) 3 program patients (pts) with moderate to severe UC. Methods: NMSC events were evaluated from randomized placebo-controlled studies (2 identical 8-week induction [OCTAVE Induction 1 & 2; NCT01465763, NCT01458951], a 52-week maintenance study Sustain, NCT01458574]), and ongoing open-label,...
The article "Characterization of Creatine Kinase Levels in Tofacitinib–Treated Patients with Ulcerative Colitis: Results from Clinical Trials", written by Remo Panaccione, John D. Isaacs, Lea Ann Chen, Wenjin Wang, Amy Marren, Kenneth Kwok, Lisy Gary Chan and Chinyu Su, was originally published electronically on the publisher's internet portal 20 August 2020 without open access.